-
Views
-
Cite
Cite
José M. Serratosa, Pilar Gómez-Garre, Ma Esther Gallardo, Berta Anta, Daniel Beltrán-Valero de Bernabé, Dick Lindhout, Paul B. Augustijn, Carlo A. Tassinari, Roberto Michelucci, Alain Malafosse, Meral Topcu, Djamel Grid, Charlotte Dravet, Samuel F. Berkovic, Santiago Rodríguez de Córdoba, A Novel Protein Tyrosine Phosphatase Gene Is Mutated in Progressive Myoclonus Epilepsy of the Lafora Type (EPM2), Human Molecular Genetics, Volume 8, Issue 2, February 1999, Pages 345–352, https://doi.org/10.1093/hmg/8.2.345
- Share Icon Share
Abstract
Progressive myoclonus epilepsy of the Lafora type or Lafora disease (EPM2; McKusick no. 254780) is an autosomal recessive disorder characterized by epilepsy, myoclonus, progressive neurological deterioration and glycogen-like intracellular inclusion bodies (Lafora bodies). A gene for EPM2 previously has been mapped to chromosome 6q23–q25 using linkage analysis and homozygosity mapping. Here we report the positional cloning of the 6q EPM2 gene. A microeletion within the EPM2 critical region, present in homozygosis in an affected individual, was found to disrupt a novel gene encoding a putative protein tyrosine phosphatase (PTPase). The gene, denoted EPM2, presents alternative splicing in the 5′ and 3′ end regions. Mutational analysis revealed that EPM2 patients are homozygous for loss-of-function mutations in EPM2. These findings suggest that Lafora disease results from the mutational inactivation of a PTPase activity that may be important in the control of glycogen metabolism.